| Income statement (USD) | Q2 2026 ended May 31, 2026 | Q1 2026 ended Feb 28, 2026 | Q4 2025 ended Nov 30, 2025 | Q3 2025 ended Aug 31, 2025 | Q2 2025 ended May 31, 2025 | Q1 2025 ended Feb 28, 2025 | Q4 2024 ended Nov 30, 2024 | Q3 2024 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.04M | 6.25M | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M | 12.59M |
| Research and development | 87.65M | 84.14M | 83.02M | 86.12M | 78.10M | 69.66M | 67.22M | 55.48M |
| Operating expenses | 103.25M | 98.75M | 96.67M | 99.28M | 92.38M | 81.32M | 77.94M | 67.20M |
| Operating income | -94.20M | -92.50M | -83.09M | -91.39M | -48.32M | -62.86M | -64.66M | -54.61M |
| EBITDA | -91.95M | -90.30M | -80.97M | -89.36M | -46.08M | -60.51M | -62.11M | -52.22M |
| Income before tax | -89.81M | -78.22M | -86.42M | -42.70M | -56.35M | -58.54M | -48.87M | |
| Income tax | -271.0K | 0 | 0 | 0 | 760.0K | 0 | 8.0K | 82.0K |
| Net income | -89.53M | -87.17M | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M | -48.96M |
| EPS | -0.81 | -0.79 | -0.83 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 |
| EPS (diluted) | -0.81 | -0.79 | -0.83 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 |
| Diluted shares | 111.08M | 110.07M | 2.80M | 84.16M | 83.88M | 83.56M | 3.74M | 72.78M |
| Dividends per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.